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Abstract
Background: New Zealand has a higher incidence of Staphylococcus aureus disease than other developed
countries, with significant sociodemographic variation in incidence rates. In contrast to North America, the majority
of disease is due to methicillin-susceptible S. aureus (MSSA), although relatively little is known about the comparative
demographics of MSSA and methicillin-resistant S. aureus (MRSA) infections in New Zealand.
Methods: Our objectives were to describe the trends, incidence and patient demographics of all S. aureus infections in
patients presenting to our institution between 2001 and 2011, and compare the epidemiology of MSSA and MRSA
infections. We identified all patients with S. aureus infections over the study period. A unique S. aureus infection was
defined as the first positive S. aureus culture taken from the same patient within a thirty-day period. Standard definitions
were used to classify episodes into community- or healthcare-associated S. aureus infection.
Results: There were 16,249 S. aureus infections over the study period. The incidence increased significantly over the
study period from 360 to 412 per 100,000 population (P < 0.001), largely driven by an increase in community-associated
non-invasive MSSA infections. When compared with MSSA infections, patients with non-multiresistant MRSA infections
were more likely to be older, have hospital-onset infections and be Māori or Pacific Peoples.
Conclusions: Our work provides valuable baseline data on the epidemiology and trends of S. aureus infections in New
Zealand. The significant increase in community-associated S. aureus infections is of public health importance. Future
studies should investigate the reasons underlying this concerning trend.
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Background
Staphylococcus aureus is a major human pathogen, and
infections caused by S. aureus result in significant mor-
bidity and mortality [1,2]. Although most commonly
associated with skin and soft tissue infections (SSTI),
S. aureus is also responsible for a range of serious invasive
infections, including osteomyelitis, necrotizing pneumonia
and bacteremia [3]. In addition, S. aureus disease occurs
commonly in both community and healthcare settings
amongst a variety of demographic groups [1,4,5]. To date,
many studies assessing the burden of S. aureus infections
have focused on one particular aspect of S. aureus disease,
such as a specific clinical syndrome (e.g. bloodstream
infections or SSTI), specific patients (e.g. adults only) or a
specific place of acquisition (e.g. healthcare-associated
infections) [6-8]. Furthermore, as a consequence of the
recent epidemic of community-associated methicillin
resistant S. aureus (CA-MRSA) in North America, many
studies have focused exclusively on describing the epi-
demiology and burden of MRSA infections [9,10]. As
such, population-based data on the overall extent of S.
aureus disease, regardless of clinical syndrome, healthcare
exposure or antimicrobial resistance profile, are limited.
The reported incidence of S. aureus disease in New
Zealand is higher than that from similar developed
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countries [11-13]. However, in contrast to several other
settings, particularly North America, the vast majority of
S. aureus disease in New Zealand is due to methicillin-
susceptible S. aureus (MSSA) [13-15]. Distinct demo-
graphic associations have been described for S. aureus
infections in New Zealand, including age, ethnicity and
economic deprivation [11,16,17]. To date however, rela-
tively little is known about the comparative epidemiology
of infections caused by MSSA and MRSA strains in our
setting. Moreover, no studies have systematically assessed
longitudinal trends in the overall incidence and epide-
miology of S. aureus infections in New Zealand. Accor-
dingly, we sought to: (i) describe the incidence, trends and
patient characteristics of S. aureus infections in patients
presenting to our hospital over an 11-year period, and (ii)
compare the demographics of infections caused by MSSA
and MRSA strains.
Methods
Setting, patients and isolates
Auckland District Health Board (ADHB) is a tertiary-
level, university-affiliated institution exclusively serving a
population of approximately 500,000, within a larger
metropolitan region of 1.4 million inhabitants. Auckland
is the largest city in New Zealand, and has an ethnically
diverse population, having the following major popu-
lation groups: European (52%); Asian (29%), Pacific
Peoples (11%); Māori (indigenous New Zealander, 8%)
and other ethnicities (2%) [18].
All specimens that cultured S. aureus between January
1st 2001 and December 31st 2011 were identified from
the laboratory database in the Department of Clinical
Microbiology, Auckland City Hospital, New Zealand. In
order to restrict the analysis to isolates that were likely
to represent clinically relevant infections, all screening
isolates (anterior nares; axillae; groin) and isolates from
genital swabs, pharyngeal swabs and stool were
excluded. In addition, all specimens that did not have a
culture site specified were excluded. A sterile culture site
was defined as one matching the US Centers for Disease
Control and Prevention (CDC) surveillance systems
definition [8]. A unique S. aureus infection was defined
as the first positive S. aureus culture taken from the
same patient within a thirty-day period. All S. aureus
isolates were identified using standardised laboratory
protocols. Antimicrobial susceptibility testing was per-
formed by agar dilution and results were interpreted
according to Clinical and Laboratory Standards Institute
recommendations [19]. In keeping with previous studies,
strains that were phenotypically resistant to <3 non
β-lactam antimicrobials were defined as non-multidrug-
resistant MRSA (nmMRSA), and strains that were resistant
to ≥3 non-β-lactam antimicrobials were defined as
multidrug-resistant MRSA (mMRSA) [20,21].
Data collection
The following demographic information was extracted
from the hospital administrative database about each pa-
tient who had an inpatient hospital admission associated
with a positive S. aureus culture: age, gender, ethnicity,
residence in a long term care facility, and number
of previous hospitalizations in the preceding twelve
months. In addition, hospital discharge diagnoses related
to each hospital admission (coded using the International
Classification of Diseases, Tenth Edition, [ICD-10] codes)
were obtained for each patient. The NZ Deprivation index
(NZDep) score was used to assign socioeconomic status
to each patient. This score is an area-based measure of
deprivation derived from New Zealand census data, and is
based on various measures of deprivation, including:
household income, household ownership, household occu-
pancy, employment and education levels, and access to
telecommunications [22]. It is expressed as a score
between one and ten, a score of ten representing the most
deprived neighbourhoods.
Population denominator information for the ADHB
catchment region was obtained from the 2001 and 2006
New Zealand censuses, and from linear interpolation
between census data for the study period [18]. For analysis,
ethnicity was grouped into four major groupings:
European, Māori, Pacific Peoples and Other ethnicities.
Definitions of Staphylococcus aureus-related hospital
admissions
Based on previously described methodology, a list of
ICD-10 codes for S. aureus-related clinical syndromes
were developed (a detailed list of codes are shown in
Additional file 1) [23-25]. These syndromes were: (i) skin
and soft tissue infection (SSTI); (ii) musculoskeletal
infection; (iii) respiratory infection; (iv) endovascular
infection; (v) central nervous system infection, and (vi)
sepsis/bacteremia. For analysis, these categories were
further classified as either non-invasive infections (SSTI)
or invasive infections (all other clinical syndromes). All
S. aureus bloodstream infection were classified as invasive
infections. In addition, other invasive S. aureus infections
were defined by the isolation of S. aureus from a clinical
specimen, plus ≥1 ICD-10 discharge diagnoses associated
with an invasive clinical syndrome (Additional file 1). For
positive S. aureus culture results with ≥1 ICD-10 discharge
codes associated with an invasive clinical syndrome, the
principal discharge code was regarded as the most likely
clinical syndrome. A non-invasive infection was defined as
the isolation of S. aureus from a non-sterile site, with a
principal or secondary ICD-10 discharge diagnosis asso-
ciated with a SSTI (Additional file 1) and no ICD-10 codes
associated with an invasive clinical syndrome.
Based on definitions adapted from similar studies,
[17,26] cases were described as community-associated if
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S. aureus was isolated from a patient within 48 hours
of hospital admission who: (i) had no history of
hospitalization or surgery in the preceding calendar year,
(ii) did not reside in a long-term care facility (LTCF),
and (iii) did not have any prior or current ICD-10
discharge diagnoses relating to hemodialysis. Conversely,
cases were described as healthcare-associated (HCA)
S. aureus infection if one or more of these risk factors were
documented. Healthcare-associated cases were further
classified as hospital-onset (HCA-HO) or community-
onset (HCA-CO) depending on whether the specimen was
taken > 48 hours or ≤ 48 hours respectively, following
hospital admission.
Statistical analysis
Categorical variables were compared using the χ2 or
Fisher’s exact test as appropriate. Non-parametric data
were compared using the Mann–Whitney U test or
Kruskal-Wallis test. Incidence rates were calculated per
100,000 population, and a Poisson log-linear regression
model was used to assess trends in incidence rates using
log population denominator data as the offset variable.
Multivariate logistic regression analysis using a stepwise
backward elimination model was used to identify factors
associated with nmMRSA infections. All statistical ana-
lysis was performed using GraphPad Prism (Version
5.02) or STATA (Version 11) and a two-tailed P value
of < 0.05 was considered significant.
Ethics
Auckland District Health Board, New Zealand, granted
institutional approval for this study.
Results
Patients and incidence rates
Over the 11-year study period there were 26,244 unique
S. aureus isolates identified from the laboratory database,
including 16,249 patients with ≥1 ICD-10 discharge
diagnoses consistent with a S. aureus-related clinical












































































































































Figure 1 Incidence of Staphylococcus aureus infections per 100,000 population per year in patients hospitalized at Auckland District
Health Board, New Zealand, 2001–2011, stratified by (A) place of acquisition; (B) invasive vs. non-invasive infection and (C) MSSA
vs. MRSA. Abbreviations: CA, community-associated; HCA-CO, healthcare-associated, community-onset; HCA-HO, healthcare-associated,
hospital-onset; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; NS, not significant.







































































































































































































Figure 2 (See legend on next page.)
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classified as having an invasive infection, and 12,497/
16,249 (77%) as having a non-invasive infection. Overall,
8,754/16,249 (54%) of infections were classified as
community-associated, 5,523/16,249 (34%) as HCA-CO,
and 1,972/16,249 (12%) as HCA-HO (Figure 1). The
11-year averaged incidence of all S. aureus related-
hospitalizations over the study period was 366 per
100,000 population per year, and increased significantly
from 360 per 100,000 population in 2001, to 412 per
100,000 population in 2011 (P < 0.001). This rise was
related to significant increases in community-associated
(P < 0.001) and HCA-CO (P = 0.02) infections (Figure 1A);
non-invasive (P < 0.001) infections (Figure 1B); and those
caused by MSSA strains (P < 0.001) (Figure 1C). The inci-
dence of invasive S. aureus infections decreased signifi-
cantly over the study period from 102 to 73 per 100,000
population per year (P < 0.001) (Figure 1B), and there was
no significant change in the incidence of HCA-HO infec-
tions (Figure 1A). When stratified by age (Figure 2A), the
incidence of S. aureus-related hospitalizations was highest
in the under five and over 75 year age groups (1305 and
646 per 100,000 population per year respectively), and
when stratified by ethnicity (Figure 2B), the incidence was
highest in Māori and Pacific Peoples (981 and 873 per
100,000 population per year respectively). In addition,
when stratified by NZDep score (Figure 2C), the highest
incidence of S. aureus-related hospitalizations was in
those patients residing in areas of high socioeconomic
deprivation (higher NZDep scores) (Figure 2C).
Characteristics of Staphylococcus aureus infections
in relation to place of acquisition and clinical syndrome
The median age of all patients with S. aureus infections
was 22 years (interquartile range [IQR] 6–50). There
was a statistically significant gradient in the age distribu-
tion of patients according to place of acquisition, with
the median age highest in patients with HCA-HO infec-
tions (median age 40 years, IQR 8–67), and lowest in
patients with community-associated infections (median
age 13 years, IQR 4–37) (Table 1). The proportion of
(See figure on previous page.)
Figure 2 Incidence of Staphylococcus aureus infections per 100,000 population per year in patients hospitalized at Auckland District
Health Board, New Zealand, 2001–2011, stratified by (A) age; (B) ethnicity; and (C) NZDep score according to (i) place of acquisition
and (ii) MSSA, nmMRSA and mMRSA. Abbreviations: CA, community-associated; HCA-CO, healthcare-associated, community-onset; HCA-HO,
healthcare-associated, hospital-onset; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus;
NZDep, New Zealand Deprivation Index (1 = least deprived, 10 =most deprived).
Table 1 Characteristics and patient demographics of Staphylococcus aureus infections, Auckland District Health Board,
New Zealand, 2001–2011








(HCA-CO) (n = 5,523)
Healthcare-associated,
hospital-onset
(HCA-HO) (n = 1,972)
P value
Age, median, years (IQR) 22 (6 – 50) 13 (4 – 37) 35 (10 – 60) 40 (8 – 67) < 0.001c
Gender, male 9,098 (56) 4,967 (57) 2,965 (54) 1,166 (59) < 0.001d
Clinical syndrome
Invasive 3,752 (23) 1,220 (14) 1,427 (26) 1,105 (56) < 0.001d
Non-invasive 12,497 (77) 7,534 (86) 4,096 (74) 867 (44) -
Ethnicitya
European 6,824 (42) 3,114 (36) 2,658 (48) 1,052 (54) < 0.001d
Māori 3,211 (20) 1,908 (22) 978 (18) 325 (17) < 0.001d
Pacific peoples 4,802 (30) 2,932 (34) 1,444 (26) 426 (22) < 0.001d
Other 1,327 (8) 743 (8) 427 (8) 157 (8) 0.25d
NZDepb
1–3 3,093 (20) 1,553 (19) 1,105 (21) 435 (23) < 0.001 d
4–7 5,443 (35) 2,780 (34) 1,976 (37) 687 (37)
8–10 6,861 (45) 3,915 (47) 2,202 (42) 744 (40) 0.015 d
< 0.001 d
aData available for 16,164 infections (8,697 CO; 5,507 HCA-CO; 1,960 HCA-HO).
bData available for 15,397 infections (8,248 CO; 5,283 HCA-CO; 1,866 HCA-HO).
cP value calculated using Kruskal-Wallis test.
dP value calculated using χ2 test.
Abbreviations: IQR interquartile range, MSSA methicillin-susceptible Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, CO community-onset,
HCA-CO healthcare-associated, community-onset, HCA-HO healthcare-associated, hospital-onset.
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patients with invasive infections differed significantly
according to place of acquisition, with 56% of HCA-HO
infections classified as invasive, compared to only 26% of
HCA-CO and 14% of community-associated infections
(P < 0.001). Patients of European ethnicity were more
likely to have HCA-HO infections than community-
associated infections (54% vs. 36%; P < 0.001), whereas
Māori or Pacific patients were more likely to have
community-associated than HCA-HO infections (22% vs.
17%; P < 0.001 and 34% vs. 22%; P < 0.001 respectively)
(Table 1). In addition, there was variation in the socioeco-
nomic distribution of S. aureus infections across acquisition
category, such that patients residing in less deprived areas
were more likely to have HCA-HO infections than
community-associated infections (23% vs. 19%; P < 0.001).
Conversely, patients in more deprived areas were more
likely to have community-associated infections than
HCA-HO infections (47% vs. 40%; P < 0.001) (Table 1).
Comparison of MSSA, nmMRSA and mMRSA infections
The incidence of MSSA infections increased significantly
from 306 per 100,000 in 2001 to 361 per 100,000 in
2011 (P < 0.001). In contrast, the incidence of MRSA did
not increase over the study period (Figure 1). Overall,
1,957/16,249 (12%) of infections were caused by MRSA
(1,804 [94%] nmMRSA and 117 [6%] mMRSA). There
were distinct demographic differences between patients
with MSSA, nmMRSA and mMRSA infections, such
that patients with mMRSA infections were significantly
older than patients with either MSSA (median 52 years
vs. 22 years; P < 0.001) or nmMRSA (median 52 years
vs. 16 years; P < 0.001), and were more likely to have
invasive infections than patients with MSSA (44% vs.
24%; P < 0.001) or nmMRSA (44% vs. 17%; P < 0.001).
Patients with MSSA or nmMRSA did not differ signifi-
cantly according to the place of acquisition of their
infection (Table 2). However, when compared to patients
with nmMRSA, patients with mMRSA infections were
significantly more likely to have HCA-CO or HCA-HO
infections (50% vs. 33%; P < 0.001 and 25% vs. 13%;
P < 0.001, respectively).
Given that the number of patients with mMRSA infec-
tions was relatively small (n = 117) compared to patients
with MSSA (n = 14,292) or nmMRSA (n = 1,840), we
Table 2 Patient characteristics associated with methicillin-susceptible Staphylococcus aureus (MSSA) infections,
non-multidrug resistant methicillin resistant S. aureus (nmMRSA) infections and multidrug resistant MRSA (mMRSA)







P OR of MSSA vs.
nmMRSA (95% CI)
P OR nmMRSA vs.
mMRSA infection (95% CI)
Age, median, IQRa 22 (6–50) 16 (3–47) 52 (31.5–71.5) < 0.001 - < 0.001 -
Male sexb 8,028 (56) 1,005 (55) 69 (59) 0.34 1.19 (0.83–1.69) 0.23 0.85–1.04
Clinical syndromeb
Invasive 3,390 (24) 311 (17) 51 (44) < 0.001 1.53 (1.35–1.74) < 0.001 0.26 (0.18–0.39)
Non-invasive 10,902 (76) 1,529 (83) 66 (56) - - - -
Place of acquisitionb
CO 7,732 (54) 993 (54) 29 (25) 0.93 1.0 (0.91–1.11) < 0.001 3.56 (2.32–5.47)
HCA-CO 4,851 (34) 614 (33) 58 (50) 0.64 1.03 (0.93–1.14) < 0.001 0.51 (0.35–0.74)
HCA-HO 1,709 (12) 233 (13) 30 (25) 0.40 0.94 (0.81–1.08) < 0.001 0.42 (0.27–0.65)
Ethnicityb, c
European 6,223 (44) 544 (30) 57 (49) < 0.001 1.84 (1.65–2.04) < 0.001 0.44 (0.30–0.64)
Māori 2,845 (20) 349 (19) 17 (15) 0.37 1.06 (0.94–1.19) 0.27 1.37 (0.81–2.33)
Pacific Peoples 3,942 (28) 832 (46) 28 (24) < 0.001 0.41 (0.37–0.46) < 0.001 2.92 (1.89–4.51)
Other 1,210 (8) 103 (5) 14 (12) < 0.001 1.56 (1.27–1.92) 0.013 0.44 (0.24–0.79)
NZDep bandb,d
1–3 2,792 (21) 275 (16) 26 (25) < 0.001 1.37 (1.20-1.57) 0.029 0.58 (0.37-0.92)
4–7 4,864 (36) 546 (32) 33 (31) < 0.001 1.21 (1.09-1.35) 1.0 1.02 (0.67-1.56)
8–10 5,903 (44) 911 (53) 47 (44) < 0.001 0.69 (0.63-0.77) 0.11 1.39 (0.94-2.07)
aP value calculated using Kruskal Wallis test.
bP value calculated using χ2 test.
cData available for 16,164 infections (14,220 MSSA, 1,828 nmMRSA and 116 mMRSA).
dData available for 15,397 infections (13,559 MSSA, 1,732 nmMRSA and 106 mMRSA).
Abbreviations: OR odds ratio, CI confidence interval, IQR interquartile range, MSSA methicillin-susceptible Staphylococcus aureus, nmMRSA non-multidrug resistant
methicillin-resistant Staphylococcus aureus, mMRSA multidrug resistant methicillin-resistant Staphylococcus aureus, CO community-onset, HCA-CO healthcare-associated,
community-onset, HCA-HO healthcare-associated, hospital-onset.
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concentrated on comparing risk factors associated with
either MSSA or nmMRSA infections (Table 3). On
multivariate analysis, factors associated with nmMRSA
isolation were: age over 75 years (odds ratio (OR), 1.77
[95% CI, 1.44-2.17]); Māori or Pacific ethnicity (OR, 1.48
[95% CI, 1.26-1.75] and OR, 2.41 [95% CI, 2.09-2.78] re-
spectively); and HCA-HO infection (OR, 1.37 [95% CI,
1.15-1.62]). In addition, nmMRSA infections were less
likely to be invasive than MSSA infections (OR 0.64
[95% CI, 0.55-0.74]).
Discussion
In this study, we systematically assessed the trends, inci-
dence and demographics of patients hospitalized with
S. aureus infections in our setting. We found notable demo-
graphic differences between community and healthcare-
associated S. aureus infections, as well as differences in
the comparative epidemiology of MSSA and MRSA. Our
findings have implications for the following reasons.
First, by assessing all S. aureus infections, rather than
just one specific aspect such as MRSA or nosocomial
infections, our data provide a broad and comprehensive
representation of the trends and burden of S. aureus
disease in our setting. We observed an increase in the
overall incidence of S. aureus infection, largely driven by
an increase in community-associated non-invasive infec-
tions. Our finding of a significant increase in the incidence
of hospitalizations for skin infections is in keeping
with other recent studies in New Zealand [11,23,24],
and further highlights this concerning national trend.
Although reasons for this increase are unclear, suggested
contributory factors include delayed access to healthcare,
increases in household crowding and declining socio-
economic circumstances for specific population groups
[23,24]. However, in contrast to the increase in non-
invasive infections, the incidence of invasive S. aureus
infections decreased significantly over the study period
from 102 to 73 per 100,000 population per year (P < 0.001).
This trend is in keeping with recent reports from North
America, [10,27,28] and may, in part, be due to improved
local infection control practices, such as improvements
in hand hygiene compliance and measures to reduce
healthcare-associated bloodstream infections, including
those caused by S. aureus [29].
Second, we found that in our setting, the vast majority
(88%) of S. aureus infections were caused by MSSA, and
the incidence of MSSA increased significantly over the
study period. Conversely, the incidence of MRSA infec-
tions remained stable; therefore the percentage contribu-
tion of MRSA to the overall burden of S. aureus disease
actually decreased. This finding is in sharp contrast to
North America, where studies suggest approximately
40-60% of S. aureus infections are caused by MRSA,
largely due to the epidemic spread of the USA300 clone
[10,28]. However, despite the large burden of MSSA
infections in our setting, relatively little is known about
the molecular epidemiology of MSSA strains in New
Zealand. In particular, the extent to which the observed
increase in community-associated MSSA SSTI is driven
by the spread of one MSSA clone, or is due to a range of
MSSA lineages is unknown. Interestingly, after multi-
variate analysis, we found that nmMRSA infections were
more common than MSSA infections in Māori and
Pacific Peoples compared to European patients. The
reasons for this observation are unclear, although
numerous studies have described an association between
nmMRSA isolation and other distinct ethnic groups, for
example African-Americans [28] and Australian Aboriginals
[21]. Moreover, an association between specific community-
associated MRSA clones and Indigenous ethnic groups
Table 3 Multivariate analysis of factors associated
with non-multidrug resistant methicillin-resistant
Staphylococcus aureus (nmMRSA) infections, Auckland
District Health Board, New Zealand, 2001-2011








15 to 49 Reference
Under 5 0.98 (0.85–1.14)
5 to 14 1.12 (0.97–1.29)
50 to 74 1.09 (0.92–1.08)








4–7 (medium) 0.98 (0.84–1.15)





Abbreviations: OR odds ratio, CI confidence interval, MSSA methicillin-susceptible
Staphylococcus aureus, nmMRSA non-multidrug resistant methicillin-resistant
Staphylococcus aureus, CO community-onset, HCA-CO healthcare-associated,
community-onset, HCA-HO healthcare-associated, hospital-onset.
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has recently been demonstrated in New Zealand [17].
Future work should investigate the possible host,
bacterial and socioenvironmental factors that pre-
dispose such groups to infection with certain MRSA
clones.
In our locale, patients with multiresistant MRSA rep-
resented a distinct epidemiological group, in that they
were older, more likely to be European and more likely
to have healthcare-associated infections than patients
with MSSA or nmMRSA. This finding is consistent with
a recent study from our setting, which showed that
specific multiresistant MRSA clones (e.g. sequence type
(ST) 22 MRSA and ST239 MRSA) were associated with
prior healthcare exposure, and were more likely to be
isolated from older European patients [17]. It is possible
that our observation may reflect circulation and acqui-
sition of mMRSA in long-term residential care
facilities, with elderly European patients markedly
overrepresented in long-term residential care facilities
in New Zealand compared to non-European and Indi-
genous groups [30].
There were several limitations with our study. In par-
ticular, our analysis was restricted to patients with
S. aureus-related hospitalizations, and did not include
patients who only received treatment in primary care.
Furthermore, we used a relatively conservative and
specific method of case ascertainment in that we only
included patients who had culture-proven S. aureus
disease plus a hospital discharge code describing a
S. aureus-related clinical syndrome, rather than all
patients who had a positive S. aureus culture. Moreover,
most patients discharged from hospital with an infec-
tious disease diagnosis do not have any identified etio-
logical agent [24]. As such, the true burden of S. aureus
disease in our setting is likely to be considerably higher.
In addition, we did not have patient-level information on
factors such as medical co-morbidities or antibiotic usage.
However, our main aim was not to provide detailed
descriptive information on specific clinical syndromes, but
rather to provide a broad overview of the demographics
and trends of a large number of S. aureus infections.
Conclusions
In conclusion, our study provides valuable baseline in-
formation on the epidemiology and trends of S. aureus
infections in a New Zealand population. There were
notable sociodemographic differences in disease burden,
with the incidence highest in Māori and Pacific Peoples.
Importantly, we observed a steady and significant
increase in S. aureus infections, predominantly due to
a rise in non-invasive community-associated MSSA.
Future work should investigate the clinical and molecu-
lar epidemiological associations underlying this concern-
ing trend.
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